The Schall Law Firm Begins Probe Into Claims Against Allakos Inc And Urges Affected Investors To Participate

LOS ANGELES, CA / ACCESSWIRE / June 25, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Allakos Inc. ("Allakos" or "the Company") (NASDAQ:ALLK) for violations of the securities laws.

The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. Allakos is the subject of a report by Zacks Equity Research on January 17, 2024. According to the report, the Company's shares "plunged 60.2% on Tuesday after management announced disappointing results from two mid-stage studies evaluating its lead pipeline drug lirentelimab (AK002) in two inflammatory conditions."

If you are a shareholder who suffered a loss, click here to participate.

We also encourage you to contact Brian Schall of the Schall Law Firm, 2049 Century Park East, Suite 2460, Los Angeles, CA 90067, at 310-301-3335, to discuss your rights free of charge. You can also reach us through the firm's website at www.schallfirm.com, or by email at bschall@schallfirm.com.

The Schall Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.